Abstract：
Solid organ transplantation represents the best (and in many cases only) treatment option for patients with end-stage organ failure. The effectiveness and functioning life of these transplants has improved each decade due to surgical and clinical advances, and accurate histocompatibility assessment. Patient exposure to alloantigen from another individual is a common occurrence and takes place through pregnancies, blood transfusions or previous transplantation. Such exposure to alloantigen\'s can lead to the formation of circulating alloreactive antibodies which can be deleterious to solid organ transplant outcome. The purpose of these guidelines is to update to the previous BSHI/BTS guidelines 2016 on the relevance, assessment, and management of alloantibodies within solid organ transplantation.
摘要：
实体器官移植代表了终末期器官衰竭患者的最佳（并且仅在许多情况下）治疗选择。由于手术和临床的进步，这些移植的有效性和功能寿命每十年都在提高。和准确的组织相容性评估。患者暴露于来自另一个个体的同种抗原是常见的，并且发生在怀孕期间。输血或先前的移植。这种同种异体抗原的暴露可导致循环同种异体反应性抗体的形成，这对实体器官移植结果有害。这些指南的目的是更新到以前的BSHI/BTS指南2016的相关性，评估，以及实体器官移植中同种抗体的管理。
